AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
isoprenaline ๐ถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| bronchodilators, phenethylamine derivatives | 1499 | 7683-59-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 90 | mg | O |
| 90 | mg | P |
| 0.64 | mg | Inhal.aerosol |
| 10 | mg | Inhal.solution |
| 40 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.79 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 56 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.71 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.41 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GRK3,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 71 | |||
| kinase-selectivity-class | AXL,CDK4,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK8,SYK,TEK,TGFBR1 | 11 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 9, 1956 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 96.40 | 77.01 | 69 | 417 | 1384229 | 89243732 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 184.95 | 64.05 | 46 | 464 | 26704 | 42594121 |
| Drug ineffective | 83.71 | 64.05 | 64 | 446 | 630133 | 41990692 |
| Torsade de pointes | 75.39 | 64.05 | 18 | 492 | 8576 | 42612249 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 170.89 | 63.15 | 48 | 965 | 56679 | 110531607 |
| Drug ineffective | 155.94 | 63.15 | 119 | 894 | 1520421 | 109067865 |
| Torsade de pointes | 114.95 | 63.15 | 29 | 984 | 22571 | 110565715 |
| Ventricular tachycardia | 83.88 | 63.15 | 27 | 986 | 49982 | 110538304 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01CA02 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
| ATC | R03AB02 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Non-selective beta-adrenoreceptor agonists |
| ATC | R03AK02 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
| ATC | R03CB01 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Non-selective beta-adrenoreceptor agonists |
| ATC | R03CB51 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Non-selective beta-adrenoreceptor agonists |
| FDA MoA | N0000000245 | Adrenergic beta-Agonists |
| FDA EPC | N0000175555 | beta-Adrenergic Agonist |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:35522 | ฮฒ-adrenergic agonist |
| CHEBI has role | CHEBI:35523 | bronchodilator agent |
| CHEBI has role | CHEBI:35524 | sympathomimetic agent |
| CHEBI has role | CHEBI:38147 | cardiotonic drug |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
Related Drugs by ATC class:
C01CA Adrenergic and dopaminergic agents 25 drugs
R03AB Non-selective beta-adrenoreceptor agonists 1 drug
R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 13 drugs
R03CB Non-selective beta-adrenoreceptor agonists 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypovolemic shock | indication | 39419009 | |
| Low cardiac output syndrome | indication | 44088000 | |
| Common cold | indication | 82272006 | DOID:10459 |
| Atrioventricular block | indication | 233917008 | DOID:0050820 |
| Cardiac arrest | indication | 410429000 | DOID:0060319 |
| Syncope due to Heart Block | indication | ||
| Thick Bronchial Secretions | indication | ||
| Tachyarrhythmia | contraindication | 6285003 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Angina pectoris | contraindication | 194828000 | |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Digitalis Toxicity with AV Conduction Defects | contraindication | ||
| Atrioventricular Conduction Defect | contraindication | ||
| Tachycardia due to Digitalis Toxicity | contraindication |
๐ถ Veterinary Drug Use
None
๐ถ Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.97 | acidic |
| pKa2 | 12.82 | acidic |
| pKa3 | 13.92 | acidic |
| pKa4 | 8.94 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | AGONIST | EC50 | 9 | WOMBAT-PK | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | AGONIST | EC50 | 9.80 | WOMBAT-PK | CHEMBL | |||
| D(2) dopamine receptor | GPCR | Ki | 4.92 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 5.33 | CHEMBL | |||||
| Beta-3 adrenergic receptor | GPCR | AGONIST | EC50 | 8.50 | WOMBAT-PK | ||||
| D(4) dopamine receptor | GPCR | Ki | 5.54 | CHEMBL | |||||
| Taste receptor type 2 member 14 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 46 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 38 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 39 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 40 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 41 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 43 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 31 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 45 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 30 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 19 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 20 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 50 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 60 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 42 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 16 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 13 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 10 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 9 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 8 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 7 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 5 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 4 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 3 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Taste receptor type 2 member 1 | GPCR | EC50 | 8.31 | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.75 | DRUG MATRIX | |||||
| Beta-2 adrenergic receptor | GPCR | EC50 | 7.54 | CHEMBL | |||||
| Beta-2 adrenergic receptor | GPCR | Kd | 6.48 | CHEMBL | |||||
| Beta-1 adrenergic receptor | GPCR | IC50 | 6.22 | CHEMBL | |||||
| Beta-2 adrenergic receptor | GPCR | IC50 | 6 | CHEMBL | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 6.87 | CHEMBL | |||||
| Beta-3 adrenergic receptor | GPCR | AGONIST | Ki | 5.30 | IUPHAR | ||||
| Beta-3 adrenergic receptor | GPCR | AGONIST | Ki | 5.30 | IUPHAR | ||||
| Beta-1 adrenergic receptor | GPCR | Ki | 6.66 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019793 | VUID |
| N0000147882 | NUI |
| D01390 | KEGG_DRUG |
| 51-30-9 | SECONDARY_CAS_RN |
| 4018235 | VANDF |
| 4018236 | VANDF |
| 4019793 | VANDF |
| C0022245 | UMLSCUI |
| CHEBI:64317 | CHEBI |
| 5FW | PDB_CHEM_ID |
| CHEMBL434 | ChEMBL_ID |
| DB01064 | DRUGBANK_ID |
| CHEMBL1711 | ChEMBL_ID |
| CHEMBL3989521 | ChEMBL_ID |
| 3779 | PUBCHEM_CID |
| 536 | IUPHAR_LIGAND_ID |
| 6078-56-4 | SECONDARY_CAS_RN |
| 6054 | RXNORM |
| 2959 | MMSL |
| 4931 | MMSL |
| 4932 | MMSL |
| 71960 | MMSL |
| d00697 | MMSL |
| 001778 | NDDF |
| 001779 | NDDF |
| 001780 | NDDF |
| 29301006 | SNOMEDCT_US |
| 372781009 | SNOMEDCT_US |
| 49602000 | SNOMEDCT_US |
| 57845006 | SNOMEDCT_US |
| D007545 | MESH_DESCRIPTOR_UI |
| 4201 | INN_ID |
| L628TT009W | UNII |
| L628TT009W | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ISOPROTERENOL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-9501 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 15 sections |
| ISOPROTERENOL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-9502 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 15 sections |
| Isoproterenol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-364 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 22 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-011 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-015 | INJECTION, SOLUTION | 0.20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-660 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 18 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-661 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 18 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-324 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 24 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-294 | INJECTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-330 | INJECTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54879-039 | INJECTION, SOLUTION | 1 mg | INTRACARDIAC | ANDA | 18 sections |
| Isoproterenol Hydrochloride | Human Prescription Drug Label | 1 | 55150-316 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | Human Prescription Drug Label | 1 | 55150-317 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
| isoproterenol hydrochloride | Human Prescription Drug Label | 1 | 68083-585 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 22 sections |
| isoproterenol hydrochloride | Human Prescription Drug Label | 1 | 68083-586 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 22 sections |
| ISOPROTERENOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-521 | INJECTION, SOLUTION | 0.20 mg | INTRACARDIAC | ANDA | 16 sections |
| ISOPROTERENOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-522 | INJECTION, SOLUTION | 1 mg | INTRACARDIAC | ANDA | 16 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-731 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-731 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-735 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-735 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1604 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1605 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-113 | INJECTION | 0.20 mg | INTRAVENOUS | ANDA | 15 sections |
| Isoproterenol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83634-303 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 24 sections |